Streptococcus UTI: Causes, Symptoms, and Treatment

Urinary tract infections caused by Streptococcus, particularly Group B Streptococcus (GBS, also known as Streptococcus agalactiae), are genuinely uncommon compared to the typical UTI caused by E. coli, but they do occur and can be clinically significant. A large study of over 20,000 patients with GBS found in their urine showed that roughly 15% of them were diagnosed and treated for an actual UTI, while the rest had bacteria present without symptoms.¹ That distinction between harmless colonization and genuine infection sits at the heart of what makes streptococcal UTIs tricky for both patients and clinicians.

Which Streptococcus Species Cause UTIs

When people talk about a “strep UTI,” they almost always mean Group B Streptococcus. This is the same bacterium that pregnant women are routinely screened for in late pregnancy because of its potential to cause serious infections in newborns. But GBS does not limit itself to expectant mothers. It colonizes the gastrointestinal and genitourinary tracts of a substantial portion of the general population, and from there it can ascend into the urinary tract and, in the right circumstances, cause infection. A case series from Eastern India highlighted this emerging role, noting that GBS is an uncommon but increasingly recognized cause of UTI in adults who are not pregnant.²

Other streptococcal species show up in urine cultures occasionally, but GBS dominates the clinical literature on streptococcal UTI. The reason is partly biological: GBS has surface proteins and toxins that allow it to adhere to and invade bladder cells, giving it a foothold that many other streptococcal species lack. Research on the virulence mechanisms of urinary strains has shown that a toxin called beta-hemolysin/cytolysin plays a central role in how these bacteria damage bladder tissue and provoke inflammation.³

Who Is Most at Risk

Streptococcal UTIs don’t affect everyone equally. Several overlapping risk factors increase your chances of developing one:

Older age: Studies consistently find that older adults are more likely to develop symptomatic GBS UTI. In the large cohort mentioned above, people diagnosed with GBS UTI were on average in their mid-60s, and increasing age was independently associated with acute infection.⁴
Chronic illness: Patients treated for GBS UTI had significantly more underlying health conditions than those with GBS in their urine who stayed symptom-free.¹
Female sex: As with most UTIs, women are disproportionately affected. In a pediatric series of 21 children with GBS UTI, 17 were female.⁵
Hospitalization: Inpatients were about three times more likely to be diagnosed with a GBS UTI than outpatients who had GBS in their urine, likely because hospital stays involve catheters, weakened immunity, and more opportunity for the bacteria to cause trouble.¹
Very young age: Newborns and infants are also vulnerable, with some cases occurring in babies less than a month old.⁵

Pregnant women deserve special mention, though their risk profile is slightly different. About one in three pregnant women carry GBS in the vaginal or rectal area, and up to half can pass the bacteria to their newborns.⁶ While the main concern during pregnancy is neonatal infection rather than the mother developing a UTI, GBS bacteriuria in a pregnant woman is treated differently than in other adults, as it signals heavy colonization and triggers antibiotic prophylaxis during labor to protect the baby.

Symptoms and How They Compare to a Typical UTI

If you have a streptococcal UTI, the symptoms you experience are broadly similar to those of any lower urinary tract infection: burning during urination, frequent urges to go, pelvic discomfort, and sometimes cloudy or blood-tinged urine. The infection can feel indistinguishable from a standard E. coli UTI based on symptoms alone, which is one reason urine cultures matter for pinning down the cause.

There are a few subtle differences worth knowing about. Animal research suggests that GBS may provoke less obvious early bladder inflammation than E. coli does. In a mouse study comparing the two organisms, E. coli triggered a massive immune response within two hours of infection, activating thousands of genes in bladder tissue. GBS, by contrast, caused no measurable early gene activation despite high bacterial loads. Even at 24 hours, GBS activated only about 170 genes compared to over 2,500 for E. coli.⁷ The practical implication is that a streptococcal UTI might initially feel milder or take longer to announce itself, though this is based on lab models rather than patient reports.

When GBS does climb higher into the kidneys, however, the story changes. Murine research has shown that GBS triggers intense inflammation and immune cell recruitment in kidney tissue, even as the bladder response stays relatively muted. This suggests that GBS may suppress some local bladder defenses while still being capable of causing serious upper tract infections like pyelonephritis.⁸ Kidney infections bring fever, flank pain, nausea, and a general feeling of being quite sick, regardless of whether the culprit is GBS or another organism.

Why Standard Urine Tests Can Miss Streptococcus

This is one of the most important practical points about streptococcal UTIs. The standard dipstick test you get at urgent care or your doctor’s office checks for two things: leukocyte esterase (a marker of white blood cells, suggesting inflammation) and nitrite (a byproduct produced when certain bacteria metabolize compounds in your urine). The nitrite test works well for E. coli and other common gram-negative bacteria that produce nitrite as they grow. Streptococcus is a gram-positive organism and does not produce nitrite, so the dipstick will come back negative for that marker even if your urine is loaded with strep bacteria.

A study that evaluated how well urinalysis predicts culture results found that the combination of leukocyte esterase and nitrite testing performed poorly for gram-positive bacteria, including S. agalactiae. The test’s accuracy score for predicting gram-positive bacteriuria was substantially lower than for gram-negative infections like E. coli.⁹ In plain terms, if your dipstick shows no nitrite but you have UTI symptoms, a streptococcal infection is one possible explanation. A urine culture, which actually grows the bacteria in the lab, is the only reliable way to identify GBS.

Newer laboratory technologies are speeding up the identification process. A direct method using mass spectrometry (MALDI-TOF) was able to identify roughly 92% of urinary microorganisms at the genus level within about an hour, compared to the 24 to 48 hours needed for standard culture.¹⁰ These faster results could help clinicians catch streptococcal UTIs sooner, particularly in patients whose dipstick tests look deceptively reassuring.

Asymptomatic Bacteriuria Versus True Infection

One of the biggest challenges with GBS in the urine is figuring out whether it actually needs to be treated. Many people, especially older adults, will have GBS show up on a urine culture without having any urinary symptoms at all. This is called asymptomatic bacteriuria, and in most non-pregnant adults, current guidelines recommend against treating it with antibiotics. The bacteria are there but are not causing disease.

The large study of over 20,000 patients with GBS bacteriuria found that only about 15% were diagnosed with a true UTI, while the remaining 85% were classified as having asymptomatic bacteriuria. Patients who were diagnosed and treated for a UTI had worse outcomes across the board: roughly 2% died within 30 days compared to 0.3% of asymptomatic patients, and 10% died within a year compared to 4%.¹ That gap almost certainly reflects the fact that people who develop symptomatic GBS UTIs tend to be sicker and more medically complex to begin with, not that treating GBS UTI itself is harmful.

The real clinical pitfall here is over-diagnosis. Some clinicians conflate the presence of white blood cells in the urine or a positive culture with a UTI, even when the patient has no urinary symptoms.¹ Older adults can have white blood cells in their urine for many reasons unrelated to infection, and GBS can colonize the urinary tract without causing harm. Treating asymptomatic bacteriuria unnecessarily exposes patients to antibiotic side effects and contributes to resistance. A retrospective study found that proteinuria and blood in the urine (hematuria) were significantly associated with actual infection as opposed to colonization, which may help clinicians distinguish the two.¹¹

The exception is pregnancy. GBS bacteriuria in a pregnant woman, even without symptoms, is clinically significant because it indicates heavy colonization and raises the risk of the baby being exposed during delivery. Pregnant women with GBS in their urine are treated and flagged for antibiotic prophylaxis during labor.⁶

Treatment Options

When a streptococcal UTI is confirmed to be causing symptoms, the good news is that GBS is generally susceptible to a range of common antibiotics. A study of 86 patients found that GBS showed very high susceptibility, above 95%, to ampicillin, amoxicillin-clavulanate, cephalothin, lincomycin, chloramphenicol, and erythromycin, with 100% susceptibility to rifampicin.¹² In practice, penicillin-family drugs like amoxicillin or ampicillin are typically the first choice, because GBS remains reliably sensitive to them and they are well tolerated.

There is a catch, though. Some of the antibiotics most commonly prescribed for typical UTIs do not work well against Streptococcus. Trimethoprim-sulfamethoxazole (the drug commonly sold under the name Bactrim) and fluoroquinolones like ciprofloxacin are go-to choices for E. coli UTIs, but GBS shows variable or poor susceptibility to trimethoprim-sulfamethoxazole in particular. If your urine culture returns GBS, your doctor may need to switch you to a penicillin-based regimen rather than sticking with the empirical antibiotic you started on. This is another reason why getting a culture, rather than relying solely on dipstick results and empirical treatment, matters when a UTI doesn’t respond to initial therapy.

For severe or complicated cases, such as kidney infections or UTIs in immunocompromised patients, intravenous antibiotics like penicillin G or ampicillin may be necessary. The duration of treatment follows general UTI guidelines: a short course for uncomplicated lower tract infections and a longer course for upper tract or complicated infections, adjusted based on culture sensitivities.

How GBS Evades Bladder Defenses

The reason GBS can sometimes persist in the urinary tract without provoking a strong immune response goes back to its biology. Research has revealed that GBS appears to actively suppress bladder inflammation during cystitis. In a mouse model, GBS caused high bacterial loads in the bladder without triggering the extensive inflammation and immune cell recruitment you would expect from a comparable E. coli infection. The bladder response to GBS was muted, while the kidney response was intense.⁸

The beta-hemolysin/cytolysin toxin is a key player in this process. Strains that produce this toxin can kill bladder cells directly, trigger inflammatory signaling molecules, and draw in immune cells called neutrophils. But paradoxically, the intense neutrophil response may not clear the bacteria effectively. Research has described this as a kind of immune subversion, where the toxin provokes inflammation that damages tissue without efficiently eliminating the bacteria.³ Not all GBS strains produce this toxin to the same degree, which helps explain why some people carry GBS in their urine harmlessly while others develop aggressive infections. The virulence of the specific strain matters as much as the vulnerability of the host.

At the cellular level, the delayed host response is striking. The gene-mapping study comparing GBS and E. coli bladder infections found that the biological pathways GBS eventually activates involve immune cell recruitment, programmed cell death, and inflammatory signaling, but they kick in much later than the equivalent E. coli response.⁷ This lag time could give GBS a window to establish itself before the immune system mounts an effective defense.

Polymicrobial Infections and GBS in Context

The urinary tract is not the sterile environment it was long assumed to be. Research on the urinary microbiome has revealed that many organisms coexist in the bladder, and the interplay between them can influence whether a potentially harmful species like GBS causes disease or stays quietly in the background. The progression from asymptomatic colonization to symptomatic infection is likely shaped by interactions between traditional pathogens and the normal urinary microbiota, including roles in biofilm formation, immune modulation, and tissue damage.¹³

In practical terms, this means a urine culture that grows GBS alongside other organisms is not necessarily a straightforward diagnosis. Mixed cultures can represent contamination (especially in poorly collected specimens), co-infection, or a complex microbial community where one organism’s behavior is influenced by its neighbors. Clinicians have to weigh the culture results against your symptoms, how the sample was collected, and your overall clinical picture. A catheter specimen, for instance, is more reliable than a midstream catch for distinguishing true infection from contamination with skin or vaginal flora.

The research on polymicrobial urinary infections is still in its early stages, but it is already clear that treating the urinary tract as a monoculture problem oversimplifies what is actually happening. For someone with recurrent UTIs and cultures that keep showing GBS alongside other bacteria, understanding this complexity can be useful when discussing management with a healthcare provider. The goal is treating actual infections while avoiding unnecessary antibiotics for colonization that may never become symptomatic.

GBS Screening in Pregnancy and UTI

Screening for GBS in late pregnancy is standard practice in many countries, typically performed between weeks 35 and 37 via vaginal and rectal swabs. The primary purpose is to identify women who carry GBS and may transmit it to their newborns during delivery, not to diagnose UTIs. But there is an important overlap: if GBS turns up in a pregnant woman’s urine culture at any point during pregnancy, even at low colony counts, it is treated as evidence of significant GBS colonization.

The prevalence of GBS colonization in pregnant women varies widely by population and testing method. Across multiple studies involving over 10,000 patients, about 13% tested positive using conventional laboratory methods, while molecular tests that detect bacterial DNA returned higher rates of 37 to 45%.⁶ The gap between these numbers highlights how much the detection method matters, and raises the question of how many colonized women go undetected by conventional culture-based screening.

For pregnant women, the link between GBS bacteriuria and intrapartum antibiotic prophylaxis is direct. A systematic review and meta-analysis evaluated various strategies for preventing GBS transmission to newborns during delivery, comparing approaches like universal screening, risk-based treatment, and different antibiotic regimens.¹⁴ The consensus is that screening-based strategies followed by antibiotic prophylaxis during labor for colonized women are the most effective way to reduce early-onset GBS disease in newborns. If you had GBS show up in your urine earlier in pregnancy, that information feeds into this decision regardless of whether the bacteriuria itself caused symptoms.

When to Push for a Culture

If you have classic UTI symptoms but your dipstick test comes back negative or equivocal, it is worth asking your clinician to send a urine culture. Gram-positive organisms like Streptococcus and Enterococcus will not turn the nitrite marker positive, so a “clean” dipstick does not rule them out. The leukocyte esterase marker is more likely to be positive if there is a genuine infection, but it is not specific and can be triggered by contamination or inflammation from other causes.

A culture is also the right call if you have been treated for a UTI and your symptoms have not improved. Standard empiric therapy aimed at E. coli may miss GBS entirely, and you could spend days feeling miserable on an antibiotic that does not target the actual organism. The culture will identify the species and provide susceptibility data so your treatment can be tailored. For recurrent UTIs in particular, getting a culture rather than relying on empiric prescriptions each time can reveal an unexpected organism like GBS that might explain why previous treatments failed.